Creagan, E T <br/><br/>
Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study.  [electronic resource] 

 -  American journal of clinical oncology  Apr 1998 
 - 139-41 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0277-3732 
<br/><br/><label>Standard No.: </label>10.1097/00000421-199804000-00008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--administration & dosage<br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Carcinoma, Renal Cell--drug therapy<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Interleukin-2--administration & dosage<br/>Kidney Neoplasms--drug therapy<br/>Levamisole--administration & dosage<br/>Male<br/>Middle Aged<br/>Recombinant Proteins--administration & dosage<br/>Survival Analysis